Compare RANI & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | CHMI |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 108.3M |
| IPO Year | 2021 | 2013 |
| Metric | RANI | CHMI |
|---|---|---|
| Price | $0.84 | $2.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $7.50 | $3.00 |
| AVG Volume (30 Days) | ★ 658.7K | 293.1K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 15.09% |
| EPS Growth | ★ 57.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,633,000.00 | N/A |
| Revenue This Year | $274.77 | N/A |
| Revenue Next Year | $79.44 | $61.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 58.85 | N/A |
| 52 Week Low | $0.45 | $2.17 |
| 52 Week High | $3.87 | $3.04 |
| Indicator | RANI | CHMI |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 70.02 |
| Support Level | $0.83 | $2.55 |
| Resistance Level | $0.92 | $2.98 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 11.23 | 43.75 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.